BHBritta Höchsmann

Britta Höchsmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Britta Höchsmann has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Eltrombopag plus cyclosporine A for moderate aplastic anemia (EMAA): a placebo-controlled, double-blind, phase 3 trial

    by Britta Höchsmann, Philippe Schafhausen, Fabian Beier, Michael Heuser, Jörg Westermann, Beatrice Drexler, Alexander Röth, Regina Theresia Herbst, Mathias Hänel, Michaela Schwarz, et al.

    Eltrombopag combined with horse antithymocyte globulin and cyclosporine A (CSA) is the standard of care for patients with severe aplastic anemia who are not eligible for stem cell transplantation. No consensus exists on the optimal treatment of moderate aplastic anemia (MAA). The "Eltrombopag for MAA" (EMAA) trial is an investigator-initiated, prospective, randomized, placebo-controlled, double-blind, multicenter, phase III trial and compared eltrombopag+CSA (n=41) with placebo+CSA (n=44) as a first-line therapy for MAA patients with clinically significant cytopenia. In patients with evaluable response at week 24 (n=75), the overall response rate (ORR), including partial response (PR) and complete response (CR), was significantly higher in the eltrombopag+CSA arm (71.4%; 95% confidence interval [CI], 54.8%-83.8%) than in the placebo+CSA arm (42.5%; 95% CI, 28.5%-57.8%) (p=0.011, Fisher's exact test; primary endpoint). After response assessment at week 24 and unblinding, patients in the placebo arm without CR were switched to receive eltrombopag in addition to continued CSA. This group achieved an ORR of 73.5% by week 48 (p=0.009, McNemar test, comparing response at 24 vs. 48 weeks). Relapse rate and failure-free survival did not differ significantly among the arms. Eltrombopag was well tolerated without new safety concerns. Adding eltrombopag to CSA for first-line treatment of MAA significantly improves trilineage hematologic response at week 24 and addition of eltrombopag in patients without CR after 24 weeks of single-agent CSA treatment also significantly improves the ORR. The trial was registered at www.clinicaltrials.gov as #NCT02773225 and at European Union Drug Regulating Authorities Clincial Trials as EudraCT2014-000174-19.

  • Open Access

    Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy

    by Britta Höchsmann, Gloria F. Gerber, Wilhelm Leopold, Bhumika J. Patel, Eleni Gavriilaki, Almut Hefter, Ursula Kalhammer, Sabine Opitz, Astrid Marx-Hoffmann, Daniel B. Knight, et al.

    Ravulizumab, a humanized, long-acting monoclonal antibody against complement factor C5, is a widely used treatment for paroxysmal nocturnal hemoglobinuria (PNH). Given that pregnant women with PNH are at increased risk for complications and the safety and efficacy of ravulizumab in pregnancy is not known, we performed an international multicenter retrospective analysis of 16 patients with PNH with 19 pregnancies managed with ravulizumab and compared outcomes to 8 earlier pregnancies in the same patients treated with eculizumab. Of the 8 eculizumab-treated pregnancies, 3 resulted in miscarriages and 1 in early preterm delivery for threatened fetal demise and massive fetal growth retardation. All 19 pregnancies on ravulizumab resulted in the birth of live infants, with a median gestational age of 267 days (interquartile range [IQR], 259-275) and median birth weight of 3115 g (IQR, 2458-3349). Cord blood testing in 2 pregnancies receiving intensified ravulizumab dosing revealed detectable ravulizumab levels consistent with transplacental transfer. After a median follow-up of 16.2 months (IQR, 4.4-40.1), no developmental abnormalities or severe infectious complications were observed in the children. This retrospective analysis provides evidence for the safety and effectiveness of ravulizumab in managing PNH during pregnancy and breastfeeding with favorable maternal and fetal outcomes.


  • Open Access

    Late-onset telomere biology disorders in adults: clinical insights and treatment outcomes from a retrospective registry cohort

    by Mareike Tometten, Fabian Beier, Martin Kirschner, Yannic Schumacher, Jeanette Walter, Margherita Vieri, Kim Kricheldorf, Alexander Röth, Uwe Platzbecker, Markus Radsak, et al.

    Pathogenic germ line variants affecting proper telomere maintenance result in premature telomere shortening and cause telomere biology disorders (TBDs). Although classical dyskeratosis congenita in children is rather well defined, late-onset (“cryptic”) TBDs remain underrecognized, resulting in underdiagnosis and inadequate treatment in affected adults. Here, we present a series of adult TBD cases collected through the German TBD reference center between 2014 and 2024. Patients aged ≥18 years with an age-matched telomere length (TL) <10th percentile in lymphocytes, a detection of either a variant of uncertain significance, a pathogenic, or a likely pathogenic variant in TBD-associated genes, and available clinical data were included in this analysis. Based on this, a novel point-based algorithm for categorization into proven, probable, and suspected-only TBD cases was developed. Of 1537 TL analyses, 42 patients with proven (n = 29) or probable (n = 13) TBD were identified. The median age at first clinical manifestation and at diagnosis was 20.0 and 34.1 years, respectively. Bone marrow failure (BMF) was the most frequent manifestation observed in our cohort (73.8%), followed by liver or interstitial lung diseases (50.0% and 41.5%, respectively). Immunosuppressive therapy was administered in 6 patients with BMF, but none of them responded. In comparison, 8 of 8 evaluable patients treated with androgen derivatives showed hematologic response. Our data provide novel real-world insights into the clinical manifestation spectrum, diagnosis, clinical course, and treatment of TBD in adult, late-onset cases of this hereditary disease.


  • Open Access

    Transfusion Support

    by Hubert Schrezenmeier, Sixten Körper, Britta Höchsmann, Christof Weinstock

    Transfusions are an essential part of supportive care in the context of HCT. RBC and platelet concentrates (PCs) are the main blood products transfused in the peri-transplant period. Here we summarize indication for transfusion, selection of product type and immunohematological challenges in the context of allogeneic stem cell transplantation.


  • Open Access

    Risk factors for thromboembolic events in patients with paroxysmal nocturnal hemoglobinuria (PNH): a nested case–control study in the International PNH Registry

    by Britta Höchsmann, Regis Peffault de Latour, Anita Hill, Alexander Röth, Timothy Devos, Christopher J. Patriquin, Wen-Chien Chou, Deepak Jain, Ke Zu, Chuntao Wu, et al.

    The objective of this analysis was to identify risk factors for thromboembolic events (TE) in patients with paroxysmal nocturnal hemoglobinuria (PNH) who were not treated with C5 inhibitors. Patients with PNH and a history of ≥ 1 TE at enrollment in the International PNH Registry (NCT01374360; registration date, January 2011) were each matched with up to 5 patients without TE. Multivariable analysis was performed with the following variables: percentage glycosylphosphatidylinositol (GPI)–negative cells, high disease activity (HDA), non-TE major adverse vascular event history, and recent anticoagulation. Of 2541 eligible patients, 57 with TE and 189 matched controls were analyzed. Multivariable analysis (odds ratio [95% CI]) identified the following factors as being associated with increased thrombotic risk: patients with no history of TE (with recent anticoagulation, 9.30 [1.20–72.27]), patients with history of TE (with recent anticoagulation, 8.91 [0.86–92.62]; without recent anticoagulation, 5.33 [0.26–109.57]), patients with ≥ 30% GPI-negative granulocytes (≥ 30% to < 50%, 4.94 [0.54–45.32]; ≥ 50%, 1.97 [0.45–8.55]), or patients with lactate dehydrogenase (LDH) ratio ≥ 1.5 × upper limit of normal (ULN) plus ≥ 2 HDA criteria (2–3 criteria, 3.18 [0.44–23.20]; ≥ 4 criteria, 3.60 [0.38–33.95]). History of TE, ≥ 30% GPI-negative granulocytes, and LDH ratio ≥ 1.5 × ULN with ≥ 2 HDA criteria are TE risk factors for patients with PNH. These findings will aid physicians by providing important clinical and laboratory risk factors that can be used to identify and manage patients with PNH who are at risk of developing TE.


  • Komplementinhibitoren: neue Therapeutika – neue Indikationen

    by Britta Höchsmann, Sixten Körper, Hubert Schrezenmeier

    Das Komplementsystem, ein klassisch transfusionsmedizinisches Thema, hat in den letzten Jahren in allen Bereichen der Medizin an Bedeutung gewonnen. Komplementinhibitoren werden aufgrund eines besseren Verständnisses der Pathophysiologie unterschiedlicher Erkrankungen in einem sich stetig erweiternden Krankheitsspektrum eingesetzt. Dieses reicht von typisch komplementassoziierten Erkrankungen wie der PNH (paroxysmale nächtliche Hämoglobinurie) bis hin zu akuten Krankheitsbildern mit einer Fehlregulation des Komplementsystems, wie COVID-19. The complement system, a classical transfusion medicine topic, has gained importance in all areas of medicine in recent years. Complement inhibitors are used in a constantly expanding spectrum of diseases due to a better understanding of the pathophysiology of different diseases. This ranges from typical complement-associated diseases such as PNH (paroxysmal nocturnal hemoglobinuria) to acute clinical pictures with a dysregulation of the complement system, such as COVID-19. Publication Date: 01 June 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Bone Marrow Failure in PNH

    by Britta Höchsmann, Hubert Schrezenmeier

  • Congenital CD59 Deficiency

    by Britta Höchsmann, Hubert Schrezenmeier


  • Targeted Therapy with Eculizumab for Inherited CD59 Deficiency

    by Britta Höchsmann, Christian Dohna-Schwake, Henriette A. Kyrieleis, Ulrich Pannicke, Hubert Schrezenmeier

    Inherited CD59 deficiency is a rare disorder that manifests in childhood with recurrent hemolytic episodes and severe neurologic symptoms.1 No specific treatment exists.


  • Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test

    by B. Höchsmann, R. Leichtle, I. von Zabern, S. Kaiser, W. A. Flegel, H. Schrezenmeier

    Background/Objectives  Paroxysmal nocturnal haemoglobinuria (PNH) is characterized by intravascular haemolysis with a negative direct antiglobulin test (DAT). Eculizumab is a humanized monoclonal antibody that inhibits complement component C5 and is approved for PNH treatment. Recent publications demonstrated that some patients with PNH develop a positive DAT during eculizumab treatment. These published clinical trials investigated a highly selected patient population. Therefore, it seems important to study this topic in a general PNH patient population with a longer follow‐up.Materials and Methods  We analysed haemolytic activity, RBC transfusion requirement, effect on DAT and ferritin levels in 41 patients with PNH before and during eculizumab therapy with a median follow‐up of 24 months (range 1–63 months).Results  During eculizumab therapy, median LDH decreased (1657–258 U/l; P < 0·0001), while median haemoglobin increased (9·2–10·3 g/dl). Eighteen of 32 pts (56%) who previously required regular transfusions became transfusion independent. DAT was positive for C3d in 72·4% of 21 eculizumab‐treated pts with available DAT. Ferritin levels increased (69–348 ng/ml, P < 0·0001). This increase was more pronounced in pts with ongoing transfusion dependency during eculizumab therapy.Conclusion  Eculizumab therapy for PNH should be added to the list of possible causes for a positive DAT. Intravascular haemolysis was inhibited by eculizumab, but signs of extravascular haemolysis should be monitored. Because renal iron loss was stopped, eculizumab‐treated pts can be prone to iron overload and therefore ferritin concentrations should be monitored closely.